Floatz logo

Veliparib

Triple-Negative Breast Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

427 Active assets in the Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Veliparib is also rated in:

non-small cell lung carcinomaActive
BBB
Indicative · Phase 3
74 / 100
View asset →
small cell lung carcinomaActive
BB
Indicative · Phase 2
71 / 100
View asset →
BRCA2-related cancer predispositionDormant
BB
Indicative · Phase 2
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →